- The report contains detailed information about Novartis AG that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Novartis AG. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Novartis AG financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Novartis AG competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Novartis AG business.
About Novartis AG
Novartis AG provides healthcare solutions worldwide. The companys product portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products.
The company operates in four divisions, including Pharmaceuticals; Vaccines and Diagnostics; Sandoz; and Consumer Health.
Pharmaceuticals Division researches, develops, manufactures, distributes, and sells branded pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; immunology and infectious diseases; and other. The Pharmaceuticals Division is organized into global business franchises responsible for the marketing of various products, as well as the Novartis Oncology business unit, responsible for the global development and marketing of oncology products.
Pharmaceuticals Division Products
Cardiovascular and Metabolism
Diovan (valsartan) and Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide): These products are high blood pressure medicines (IMS data). Diovan is offered in approximately 120 countries for treating high blood pressure, in approximately 90 countries for heart failure, and in approximately 70 countries for heart attack survivors. In 2008, the U.S. Food and Drug Administration (FDA) approved Diovan HCT for the first-line treatment of hypertension in patients unlikely to achieve blood pressure control on a single agent. In January 2009, Co-Diovan was approved for treatment of high blood pressure in Japan.
Exforge (valsartan and amlodipine besylate): It is a single-pill combination of the angiotensin receptor blocker Diovan and the calcium channel blocker amlodipine besylate. It is approved in Switzerland in 2006, and in the United States and the European Union (EU) in 2007 for the treatment of high blood pressure, it is approved in approximately 90 countries and available in approximately 70. In 2008, the FDA approved Exforge for the first-line treatment of hypertension in patients likely to need multiple drugs to achieve their blood pressure goals. Exforge was approved in Japan in January 2010. Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide) is a new single pill combining three prescribed high blood pressure treatments, such as ARB (valsartan), CCB (amlodipine) and HCT (hydrochlorothiazide). In 2009, the FDA approved Exforge HCT for patients who have tried taking dual combinations of these classes without success. In 2009, Exforge HCT was approved in Switzerland for patients uncontrolled on any dual therapy, and in 2009 Exforge HCT was approved in the EU as substitution therapy for patients controlled on all three agents (individual or in combination).
Tekturna/Rasilez (aliskiren), and Valturna (aliskiren and valsartan): These are treatments for high blood pressure based on the first and only approved direct renin inhibitor. Tekturna/Rasilez was approved in the U.S. and the EU in 2007, and is available in approximately 80 countries. The product is known as Tekturna in the U.S. and Rasilez in the rest of the world. The company is investigating various Tekturna/Rasilez single-pill combination products. The first single-pill combination product, Tekturna/Rasilez with hydrochlorothiazidecalled Tekturna HCTwas approved by the U.S. in 2008 and in the EU in 2009, where it is known as Rasilez HCT. Another single-pill combination product, Tekturna/Rasilez with valsartancalled Valturna in the U.S. (and to be called Rasival in the EU)has been approved by the FDA and was launched in the United States in 2009. Rasival was filed with the EMEA in August 2009. In addition, the company initiated the ASPIRE HIGHER clinical development program, the major ongoing cardio-renal outcomes program worldwide, involving approximately 35,000 patients in 14 trials. Also in Phase III development are Tekturna/Rasilez with the calcium channel blocker amlodipine besylate and a triple-combination therapy with Tekturna/Rasilez, amlodipine besylate and a diuretic.
Gleevec/Glivec (imatinib mesylate tablets/imatinib): It is a signal transduction inhibitor approved to t
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. NOVARTIS AG COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. NOVARTIS AG BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. NOVARTIS AG SWOT ANALYSIS
4. NOVARTIS AG FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. NOVARTIS AG COMPETITORS AND INDUSTRY ANALYSIS
5.1. Novartis AG Direct Competitors
5.2. Comparison of Novartis AG and Direct Competitors Financial Ratios
5.3. Comparison of Novartis AG and Direct Competitors Stock Charts
5.4. Novartis AG Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Novartis AG Industry Position Analysis
6. NOVARTIS AG NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. NOVARTIS AG EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. NOVARTIS AG ENHANCED SWOT ANALYSIS2
9. SWITZERLAND PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. NOVARTIS AG IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. NOVARTIS AG PORTER FIVE FORCES ANALYSIS2
12. NOVARTIS AG VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Novartis AG Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Novartis AG Key Executives
Key Executives Biographies1
Key Executives Compensations1
Novartis AG Major Shareholders
Novartis AG History
Novartis AG Products
Revenues by Segment
Revenues by Region
Novartis AG Offices and Representations
Novartis AG SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Novartis AG Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Novartis AG Capital Market Snapshot
Novartis AG Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Novartis AG Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Novartis AG Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Novartis AG Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Novartis AG 1-year Stock Charts
Novartis AG 5-year Stock Charts
Novartis AG vs. Main Indexes 1-year Stock Chart
Novartis AG vs. Direct Competitors 1-year Stock Charts
Novartis AG Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?